These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8272798)

  • 1. [Drug prices in Switzerland: European comparison of "comfort" drugs].
    Vogt N; Morabia A; Dayer P
    Schweiz Med Wochenschr; 1993 Nov; 123(47):2251-4. PubMed ID: 8272798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
    Vogler S; Vitry A; Babar ZU
    Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility.
    Jung JH; Kim DJ; Suh K; You J; Lee JH; Joung KI; Suh DC
    Int J Environ Res Public Health; 2021 Jan; 18(2):. PubMed ID: 33466893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Medicine Prices in New Zealand and 16 European Countries.
    Vogler S; Kilpatrick K; Babar ZU
    Value Health; 2015 Jun; 18(4):484-92. PubMed ID: 26091603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries.
    Leopold C; Mantel-Teeuwisse AK; Vogler S; de Joncheere K; Laing RO; Leufkens HG
    Health Policy; 2013 Oct; 112(3):209-16. PubMed ID: 24060335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.
    Vokinger KN; Hwang TJ; Grischott T; Reichert S; Tibau A; Rosemann T; Kesselheim AS
    Lancet Oncol; 2020 May; 21(5):664-670. PubMed ID: 32359489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis.
    Vokinger KN; Hwang TJ; Carl DL; Laube Y; Ludwig WD; Naci H; Kesselheim AS
    Lancet Oncol; 2022 Apr; 23(4):514-520. PubMed ID: 35271804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries.
    Garattini L; Motterlini N; Cornago D
    Health Policy; 2008 Mar; 85(3):305-13. PubMed ID: 17928092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
    Martikainen J; Kivi I; Linnosmaa I
    Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allergen regulation in European countries.
    Annequin MC; Dayan-Kenigsberg J; Erlandsson-Persson K; Husager LJ; Lake O; May S; Makinen-Kiljunen S; Pini C; Schneider T
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 1999; (93):21-37; discussion 37-40. PubMed ID: 11487877
    [No Abstract]   [Full Text] [Related]  

  • 12. Spending on medicines in Israel in an international context.
    Sax P
    Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs.
    Laing RO; McGoldrick KM
    Int J Tuberc Lung Dis; 2000 Dec; 4(12 Suppl 2):S194-207. PubMed ID: 11144553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unused drugs returned to the pharmacy--new data.
    Bronder E; Klimpel A
    Int J Clin Pharmacol Ther; 2001 Nov; 39(11):480-3. PubMed ID: 11727967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Why drug prices are high in sub-Saharan Africa. Analysis of price structure: the case of Senegal].
    Guimier JM; Candau D; Garenne M; Teulières L
    Sante; 2005; 15(1):41-52. PubMed ID: 15919632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The regulation of drug prices in Italy].
    Minghetti P; Modena T
    Boll Chim Farm; 1995 Jun; 134(6):301-5. PubMed ID: 7546536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.
    Gross DJ; Schondelmeyer SW; Raetzman SO
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2004 Jun; (IB69):1-12, 1-2. PubMed ID: 15368653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.